Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans

Cancer Research

Volumn 73, Issue 4, 2013, Pages 1265-1275

  Breitbach, Caroline J ^a   Arulanandam, Rozanne ^b   De Silva, Naomi ^b   Thorne, Steve H ^d   Patt, Richard ^e   Daneshmand, Manijeh ^a   Moon, Anne ^b   Ilkow, Carolina ^b,c   Burke, James ^a   Hwang, Tae Ho ^f   Heo, Jeong ^e   Cho, Mong ^a   Chen, Hannah ^g   Angarita, Fernando A ^a   Addison, Christina ^b   McCart, J Andrea ^h   Bell, John C ^a,b,c   Kirn, David H ^a  

^a Jennerex Inc   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e RadMD   (United States)

^f Pusan National University   (South Korea)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR 2; PEXASTIMOGENE DEVACIREPVEC; SORAFENIB; VASCULOTROPIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD PRESSURE; BREAST CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INJECTION SITE BLEEDING; INJECTION SITE INFECTION; INJECTION SITE ULCER; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER PERFUSION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; TRANSGENE; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VASCULARIZATION; VIRUS REPLICATION; WOUND HEALING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELLS, CULTURED; CLINICAL TRIALS, PHASE I AS TOPIC; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RABBITS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION;

EID: 84874309252     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2687     Document Type: Article

References (44)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006;12:5018-22. (Pubitemid 44453326)
3. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
4. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997;57:3924-8.
5. EbosJM,KerbelRS.Antiangiogenictherapy:impactoninvasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21.
6. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35. (Pubitemid 40791485)
7. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009;18:189-97.
8. Mastrangelo MJ, Maguire HC Jr., Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6:409-22. (Pubitemid 129667814)
9. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006;14:361-70. (Pubitemid 44184970)
10. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42.
11. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102.
12. Katsafanas GC, Moss B. Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domainbinding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer. J Biol Chem 2004;279:52210-7.
13. Yang H, Kim SK, Kim M, Reche PA, Morehead TJ, Damon IK, et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005; 115:379-87. (Pubitemid 40385479)
14. Buller RM, Chakrabarti S, Moss B, Fredrickson T. Cell proliferative response to vaccinia virus is mediated by VGF. Virology 1988;164: 182-92.
15. Buller RM, Chakrabarti S, Cooper JA, Twardzik DR,Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 1988;62:866-74. (Pubitemid 18068645)
16. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71.
17. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985;317:813-5.
18. Alcami A, Symons JA, Smith GL. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000;74:11230-9.
19. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFRdependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 2008;5:521-30.
20. Kirn DH,WangY, Le Boeuf F, Bell J, Thorne SH. Targeting of interferonbeta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007;4:e353.
21. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti- HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16:1637-42.
22. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ,McGuire A, Parato KA, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007;15:1686-93. (Pubitemid 47289013)
23. Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, et al. Targeting tumor vasculature with an oncolytic virus. Mol Ther 2011;19:886-94.
24. Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 2010;120:1551-60.
25. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28:68-77. (Pubitemid 28299987)
26. Vultur A, Cao J, ArulanandamR, Turkson J, Jove R, Greer P, et al. Cellto- cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 2004;23:2600-16. (Pubitemid 38586314)
27. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
28. Lassau N, Koscielny S, Opolon P, De Baere T, Peronneau P, Leclere J, et al. Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 2001;36:50-5.
29. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon- induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989;81:497-502. (Pubitemid 19102217)
30. Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001;27:475-85. (Pubitemid 32436341)
31. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604.
32. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-10. (Pubitemid 36323730)
33. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011;121:1313-28.
34. Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012;20:749-58.
35. Junod AF, Petersen H, Jornot L. Thymidine kinase, thymidylate synthase, and endothelial cell growth under hyperoxia. J Appl Physiol 1987;62:10-4.
36. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9: 653-60. (Pubitemid 36749213)
37. Zhang WJ, Ye LY, WuLQ, Xin YL, Gu F, Niu JX, et al. Morphologic, phenotypic and functional characteristics of endothelial cells derived from human hepatic cavernous hemangioma. J Vasc Res 2006;43:522-32. (Pubitemid 44691404)
38. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002;4: 465-73. (Pubitemid 35417069)
39. Dvorak HF, Rickles FR. Malignancy and hemostasis. In:Colman RW, Clowes AW, George JN, Goldhaber SZ, Marder VJ, editors. Hemostasis and thrombosis. 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. p. 851-73.
40. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-5.
41. Key NS, Vercellotti GM, Winkelmann JC, Moldow CF, Goodman JL, Esmon NL, et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci U S A 1990;87:7095-9.
42. Bryant AE, Bayer CR, Chen RY, Guth PH, Wallace RJ, Stevens DL. Vascular dysfunction and ischemic destruction of tissue in Streptococcus pyogenes infection: the role of streptolysin O-induced platelet/ neutrophil complexes. J Infect Dis 2005;192:1014-22. (Pubitemid 41266798)
43. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77.
44. Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 2011;19:1170-9.